Stephens Reaffirms “Equal Weight” Rating for Health Catalyst (NASDAQ:HCAT)

Health Catalyst (NASDAQ:HCAT)‘s stock had its “equal weight” rating reissued by research analysts at Stephens in a report issued on Thursday,Benzinga reports. They currently have a $7.00 price objective on the stock. Stephens’ price target points to a potential upside of 49.89% from the company’s previous close.

Other analysts also recently issued research reports about the stock. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, January 8th. Piper Sandler decreased their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Wells Fargo & Company lowered their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Canaccord Genuity Group cut their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Finally, Royal Bank of Canada lowered their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.45.

Health Catalyst Trading Up 6.4 %

HCAT stock opened at $4.67 on Thursday. Health Catalyst has a 12 month low of $3.76 and a 12 month high of $9.24. The firm’s 50-day moving average is $5.98 and its 200 day moving average is $7.23. The company has a market capitalization of $284.16 million, a PE ratio of -3.46 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Buying and Selling at Health Catalyst

In other news, General Counsel Benjamin Landry sold 19,268 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the sale, the general counsel now owns 72,250 shares in the company, valued at approximately $601,120. This represents a 21.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now directly owns 236,950 shares of the company’s stock, valued at $2,118,333. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 87,610 shares of company stock worth $664,043 over the last quarter. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors have recently added to or reduced their stakes in HCAT. Janney Montgomery Scott LLC purchased a new position in shares of Health Catalyst in the 3rd quarter valued at approximately $897,000. Fred Alger Management LLC purchased a new position in shares of Health Catalyst in the third quarter worth $6,858,000. Millrace Asset Group Inc. acquired a new stake in shares of Health Catalyst during the third quarter worth $1,568,000. Point72 Asset Management L.P. lifted its stake in shares of Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the period. Finally, Impax Asset Management Group plc grew its holdings in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after buying an additional 360,201 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.